Optimum Investment Advisors Has $3.28 Million Position in Gilead Sciences, Inc. (GILD)

Share on StockTwits

Optimum Investment Advisors reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 50,521 shares of the biopharmaceutical company’s stock after selling 3,752 shares during the quarter. Gilead Sciences makes up 1.1% of Optimum Investment Advisors’ investment portfolio, making the stock its 17th largest holding. Optimum Investment Advisors’ holdings in Gilead Sciences were worth $3,284,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Athena Capital Advisors LLC bought a new position in Gilead Sciences in the 4th quarter worth approximately $27,000. Capital Financial Planning LLC bought a new position in Gilead Sciences in the 4th quarter worth approximately $27,000. Creative Financial Designs Inc. ADV increased its position in Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 165 shares during the period. Claybrook Capital LLC bought a new position in Gilead Sciences in the 4th quarter worth approximately $32,000. Finally, We Are One Seven LLC bought a new position in Gilead Sciences in the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 79.94% of the company’s stock.

GILD opened at $65.86 on Tuesday. The company has a market cap of $84.60 billion, a PE ratio of 10.71, a PEG ratio of 0.81 and a beta of 1.14. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.53 by $0.23. The business had revenue of $5.28 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. Gilead Sciences’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.48 earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post 6.6 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.83%. The ex-dividend date of this dividend is Thursday, June 13th. Gilead Sciences’s dividend payout ratio is presently 40.98%.

Several research analysts have commented on the company. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $69.00 price target on the stock in a research report on Tuesday, April 23rd. Mizuho set a $88.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Friday. Credit Suisse Group assumed coverage on Gilead Sciences in a research report on Monday. They issued a “neutral” rating on the stock. Evercore ISI reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday. Finally, Oppenheimer set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Ten investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $81.61.

In related news, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total value of $173,178.00. Following the sale, the director now owns 57,560 shares of the company’s stock, valued at approximately $3,691,898.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares in the company, valued at approximately $2,270,126.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,602 shares of company stock worth $1,863,445. 0.20% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This story was first published by Highlight Press and is owned by of Highlight Press. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://highlightpress.com/2019/05/21/optimum-investment-advisors-has-3-28-million-position-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

See Also: Earnings Per Share (EPS)

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.